三個皮匠報告
政策庫
new
付費
搜索

2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況-行業數據

2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況
? 凱萊英：2021年大訂單收入12.31億元，2022年大訂單收入59.1億元，2023年大訂單收入24.20億元，累計收入14.13億美元，以40%的利潤率測算，利潤5.65億美元，占 資料來源：公司公告，國盛證券研究所 Paxlovid銷售額5.94%；
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?38KB 圖片尺寸：2533*694
同報告圖片
 / 25
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第1頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第2頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第3頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第4頁
fCDliIbnsbsgfCBBREPljaDmr5QgfCDlhbbku5bnlJ/nianoja/ljaDmr5QgfAp8LS0tLS0tfC0tLS0tLS0tfC0tLS0tLS0tLS0tLXwKfCDlpJbljIUgICB8IDY1JSAgICB8IDM1JSAgICAgICAgfAp8IOmdnuWkluWMhSB8IDMwJSAgICB8IDcwJSAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5byX6Iul5pav54m55rKZ5Yip5paH77yM5Zu955ub6K+B5Yi456CU56m25omA
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第5頁
fCDlubTku70gICB8IOS4reWbve+8iOWNgeS6v+e+juWFg++8iSB8IOWFqOeQg++8iOWNgeS6v+e+juWFg++8iSB8CnwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMTggICB8IDEgICAgICAgICAgICAgICAgfCA1ICAgICAgICAgICAgICAgIHwKfCAyMDIyICAgfCAyICAgICAgICAgICAgICAgIHwgMTUgICAgICAgICAgICAgICB8CnwgMjAyNkUgIHwgMTAgICAgICAgICAgICAgICB8IDUwICAgICAgICAgICAgICAgfAp8IDIwMzBFICB8IDI1ICAgICAgICAgICAgICAgfCAxMTAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muW8l+iLpeaWr+eJueaymeWIqeaWh++8jOWbveebm+ivgeWIuOeglOeptuaJgA==
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第6頁
fCDoja/nianlkI3np7AgfCDpgILlupTnl4cgfAp8IC0tLSB8IC0tLSB8CnwgT3Jmb3JnbGlwcm9uIHwg6IKl6IOW55eH44CBMuWei+ezluWwv+eXheOAgU9TQSB8CnwgVGlyemVwYXRpZGXvvIhNb3VuamFybywgWmVwYm91bmTvvIkgfCDogqXog5bnl4fjgIEy5Z6L57OW5bC/55eFIHwKfCBJbnN1bGluIEVmc2l0b3JhIEFsZmEgfCAx5Z6L5ZKMMuWei+ezluWwv+eXhSB8CnwgTGVwb25kaXNpcmFuIHwg5Yqo6ISJ57Kl5qC356Gs5YyW5oCn5b+D6KGA566h55a+55eFIHwKfCBSZXRhdHJ1dGlkZSB8IOiCpeiDlueXh+OAgemqqOWFs+iKgueCjuOAgU9TQeOAgTLlnovns5blsL/nl4UgfAp8IFBpcnRvYnJ1dGluaWLvvIhKYXlwaXJjYe+8iSB8IOaFouaAp+a3i+W3tOe7huiDnueZveihgOeXhSB8CnwgTGViaXJpa2l6dW1hYiB8IEFS44CBQ1JTd05QIHwKfCBEb25hbmVtYWLvvIhLaXNxYWxp77yJIHwg5pep5pyf6Zi/5bCU6Iyo5rW36buY55eF44CB5Li05bqK5YmN6Zi/5bCU6Iyo5rW36buY55eFIHwKfCBSZW10ZXJuZXR1ZyB8IOaXqeacn+mYv+WwlOiMqOa1t+m7mOeXhSB8CnwgSW1maW5lc3RyYW50IHwg5Lmz6IW655mMIHwKfCBPbG9uZW1hYnNpYiB8IDFMIEtSQVMgRzEyQyArIE5TQ0xDIHwKCui1hOaWmeadpea6kO+8muekvOadpTIwMjTlubTlubTmiqXvvIzlm73nm5vor4HliLjnoJTnqbbmiYA=
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第7頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第8頁
5aW955qE77yM5Lul5LiL5piv6K+l5Zu+6KGo5Lit55qE5pWw5o2u5pW055CG5oiQ55qE6KGo5qC877yaCgp8IERpc2NvbnRpbnVhdGlvbiBSYXRlcyBkdWUgdG8gQWR2ZXJzZSBFdmVudHMgfCBUb2xlcmFiaWxpdHkgRGF0YSB8CnwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tfAp8IDMgbWcgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCA2JSAgICAgICAgICAgICAgIHwgUGxhY2VibyB8IE9yZm9yZ2xpcHJvbiAzIG1nIHwgT3Jmb3JnbGlwcm9uIDEyIG1nIHwgT3Jmb3JnbGlwcm9uIDM2IG1nIHwKfCAxMiBtZyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNCUgICAgICAgICAgICAgICB8IE5hdXNlYSAoJSkgfCAyJSAgICAgICAgICAgfCAxMyUgICAgICAgICAgfCAxOCUgICAgICAgICAgfCAxNiUgICAgICAgICAgfAp8IDM2IG1nICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCA4JSAgICAgICAgICAgICAgIHwgVm9taXRpbmcgKCUpIHwgMSUgICAgICAgICAgIHwgNSUgICAgICAgICAgIHwgNyUgICAgICAgICAgIHwgMTQlICAgICAgICAgIHwKfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgICAgICAgICAgICAgICAgICB8IERpYXJyaGVhICglKSB8IDklICAgICAgICAgICB8IDE5JSAgICAgICAgICB8IDIxJSAgICAgICAgICB8IDI2JSAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrnpLzmnaXlrpjnvZHjgIHlm73nm5vor4HliLjnoJTnqbbmiYA=
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第9頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第10頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第11頁
| 图表19 | Orforglipron结构与结合模式 |
|--------|--------------------------|
| A      | LY3502970                |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |                          |
|        |
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第12頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第13頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第14頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第15頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第16頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第17頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第18頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第19頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第20頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第21頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第22頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第23頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第24頁
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第25頁
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
2021-2023藥明康德、凱萊英、博騰股份大訂單收入利潤及占比、預估合成量情況_第26頁
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
所屬報告： CDMO行業專題：禮來新藥Orforglipron有望拉動小分子核心公司下一波提速-250523（20頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站